Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-18
2007-09-18
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S216000
Reexamination Certificate
active
10754117
ABSTRACT:
The invention provides compounds of the Formula:wherein m, n, A, X, Y, Z, R1, R2, R4, R6, R7, R8, R9and R10are as defined herein, and pharmaceutically acceptable salts, solvates, prodrugs, single isomers or racemic or non-racemic mixture of isomers thereof. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula I.
REFERENCES:
patent: 3975399 (1976-08-01), DeFranco et al.
patent: 4113873 (1978-09-01), Himizu et al.
patent: 4115401 (1978-09-01), Nanthavong et al.
patent: 4177346 (1979-12-01), Nelson
patent: 4320136 (1982-03-01), Scribner
patent: 6034093 (2000-03-01), Ewing et al.
patent: 6376533 (2002-04-01), Burk et al.
patent: 6747037 (2004-06-01), Old et al.
patent: 512960 (1980-11-01), None
patent: 841165 (1976-10-01), None
patent: 1553595 (1979-10-01), None
patent: 1569982 (1980-06-01), None
patent: 1583163 (1981-01-01), None
patent: WO-89/09800 (1989-10-01), None
patent: WO-89/11275 (1989-11-01), None
patent: WO-93/03825 (1993-03-01), None
patent: WO-96/41639 (1996-12-01), None
patent: WO-00/21532 (2000-04-01), None
patent: WO-00/21542 (2000-04-01), None
patent: WO-01/46140 (2001-06-01), None
patent: WO 03/007941 (2003-01-01), None
patent: 2004/085430 (2004-10-01), None
Zoretic et al., “Synthesis of (E)-7-[[2-[4(m-Trifluoromethylphenoxy)-3α and 3β-Hydroxy-1-butenyl]-5-oxo-1-pyrrolidinyl]]heptanoic Acids”, J. Heterocyclic Chem., Mar.-Apr. 1983, pp. 465-466, 20.
Saijo, et al., “Heterocyclic prostaglandins. IV. Synthesis of 8-aza-11-deoxyprostaglandin E1and its related compounds,”Yakugaku Zashi, 1980, pp. 3890-3895, 100(4), ABSTRACT.
Suda, et al., “Prostaglandin E Receptor Subtypes in Mouse Osteoblastic Cell Line,” Endocrinology, 1996, pp. 1698-1705, 137, No. 5.
Suzawa, et al., “The Role of Prostaglandin E Receptor Subtypes (EP1, EP2, EP3, and EP4) in Bone Resorption: An Analysis Using Specific Agonists for the Respective EPs,” Endocrinology, 2000, pp. 1554-1559, 141(4).
Ono, et al., Important role of EP4, a subtype of prostaglandin (PG) E receptor, in osteoclast-like cell formation from mouse bone marrow cells induced by PGE2, Journal of Endocrinology, 1998, pp. R1-R5, 158.
Biaggio, F.C., et al, “The Synthesis of a New i-Azaprostanoid[1]”,J. Heterocycl. Chem., May-Jun. 1989, pp. 725-728, vol. 26.
Desai Rita
Hall Robert C.
Roche Palo Alto LLC
LandOfFree
2-Piperidone derivatives as prostaglandin agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-Piperidone derivatives as prostaglandin agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-Piperidone derivatives as prostaglandin agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3784585